Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DURVALUMAB Cause Alanine aminotransferase increased? 106 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 106 reports of Alanine aminotransferase increased have been filed in association with DURVALUMAB (IMFINZI). This represents 0.6% of all adverse event reports for DURVALUMAB.

106
Reports of Alanine aminotransferase increased with DURVALUMAB
0.6%
of all DURVALUMAB reports
17
Deaths
47
Hospitalizations

How Dangerous Is Alanine aminotransferase increased From DURVALUMAB?

Of the 106 reports, 17 (16.0%) resulted in death, 47 (44.3%) required hospitalization, and 18 (17.0%) were considered life-threatening.

Is Alanine aminotransferase increased Listed in the Official Label?

Yes, Alanine aminotransferase increased is listed as a known adverse reaction in the official FDA drug label for DURVALUMAB.

What Other Side Effects Does DURVALUMAB Cause?

Death (2,817) Malignant neoplasm progression (1,330) Pneumonitis (827) Radiation pneumonitis (786) Pyrexia (573) Diarrhoea (530) Pneumonia (453) Dyspnoea (444) Interstitial lung disease (430) Off label use (395)

What Other Drugs Cause Alanine aminotransferase increased?

METHOTREXATE (2,440) RITUXIMAB (1,651) ADALIMUMAB (1,308) TOCILIZUMAB (1,163) ETANERCEPT (1,131) LEFLUNOMIDE (1,099) ACETAMINOPHEN (1,083) REMDESIVIR (1,047) FINGOLIMOD (1,020) INFLIXIMAB (981)

Which DURVALUMAB Alternatives Have Lower Alanine aminotransferase increased Risk?

DURVALUMAB vs DUTASTERIDE DURVALUMAB vs DUTASTERIDE\TAMSULOSIN DURVALUMAB vs DUVELISIB DURVALUMAB vs DYDROGESTERONE DURVALUMAB vs EBASTINE

Related Pages

DURVALUMAB Full Profile All Alanine aminotransferase increased Reports All Drugs Causing Alanine aminotransferase increased DURVALUMAB Demographics